Related Experiment Video
Updated: May 27, 2026

Simultaneous Visualization of the Dynamics of Crosslinked and Single Microtubules In Vitro by TIRF Microscopy
Published on: February 18, 2022
[mTOR complexes -- molecular spiders in molecular networks]
1I. sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary. kopper@korb1.sote.hu
Abstract:
PI3K route is one of the most outstanding signal transduction pathways, which has a key role in the decision-making processes and functions of a cell. In this network mTOR (mammalian target of rapamycin) is a well-known integrator. mTOR forms two complexes, and their increased activity is present in many human tumors. Therefore, mTOR inhibitors became more and more important in the targeted therapy, first of all in the treatment of renal cancer, neuroendocrine pancreatic cancer and certain astrocytomas, and many trials are going on in other tumor types. The therapeutic results are obvious, but problems also occur, which lead to new strategies and to the development of new drugs in order to create more individualised cancer therapy.
Insights
The PI3K/AKT/mTOR pathway is crucial in cell functions and cancer. Inhibitors targeting mTOR show promise in treating cancers like renal and pancreatic, driving personalized cancer therapy development.
Area of Science:
- Cellular signaling pathways
- Oncology
- Molecular biology
Background:
- The phosphoinositide 3-kinase (PI3K) pathway regulates critical cellular functions.
- Mammalian target of rapamycin (mTOR) is a key integrator within this pathway.
- Elevated mTOR activity is observed in numerous human cancers.
Purpose of the Study:
- To highlight the significance of the PI3K/mTOR pathway in cellular processes.
- To discuss the role of mTOR inhibitors in cancer therapy.
- To explore challenges and future directions in individualized cancer treatment.
Main Methods:
- Review of current literature on PI3K/mTOR signaling.
- Analysis of clinical trial data for mTOR inhibitors.
- Discussion of therapeutic strategies and drug development.
Main Results:
- mTOR inhibitors are effective in treating specific cancers, including renal cancer, neuroendocrine pancreatic cancer, and astrocytomas.
- Ongoing clinical trials are evaluating mTOR inhibitors in various other tumor types.
- Therapeutic outcomes demonstrate the clinical relevance of targeting the PI3K/mTOR pathway.
Conclusions:
- Targeting the PI3K/mTOR pathway is a vital strategy in oncology.
- Challenges in current therapies necessitate the development of novel drugs.
- Future research aims to refine individualized cancer therapies based on pathway modulation.
Related Concept Videos
Assembly of Complex Microtubule Structures
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Assembly of Cytoskeletal Filaments

